An eruption of basal cell carcinoma after ibrutinib

Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):334-335. doi: 10.1080/08998280.2023.2288482. eCollection 2024.ABSTRACTIbrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.PMID:38343483 | PMC:PMC10857559 | DOI:10.1080/08998280.2023.2288482
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Source Type: research